Silvan Tuerkcan
Stock Analyst at JMP Securities
(1.95)
# 3,007
Out of 4,749 analysts
147
Total ratings
34.27%
Success rate
-8%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Maintains: Market Outperform | $41 | $33.15 | +23.68% | 20 | Jan 27, 2025 | |
| JSPR Jasper Therapeutics | Reiterates: Market Outperform | $70 | $6.06 | +1,055.12% | 5 | Jan 10, 2025 | |
| CNTX Context Therapeutics | Initiates: Market Outperform | $4 | $0.91 | +337.97% | 1 | Jan 8, 2025 | |
| ENGN enGene Holdings | Reiterates: Market Outperform | $18 | $6.70 | +168.66% | 3 | Dec 23, 2024 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $41.59 | +106.78% | 13 | Dec 20, 2024 | |
| ELEV Elevation Oncology | Reiterates: Market Outperform | $7 | $0.69 | +909.81% | 5 | Dec 19, 2024 | |
| RLAY Relay Therapeutics | Reiterates: Market Outperform | $21 | $4.47 | +369.80% | 10 | Dec 12, 2024 | |
| VOR Vor Biopharma | Reiterates: Market Outperform | $12 | $1.42 | +745.07% | 11 | Dec 10, 2024 | |
| SLDB Solid Biosciences | Initiates: Market Outperform | $15 | $3.18 | +371.70% | 1 | Dec 10, 2024 | |
| PRME Prime Medicine | Initiates: Market Outperform | $10 | $2.80 | +257.14% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $20 | $4.46 | +348.43% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $1.50 | +233.33% | 11 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.00 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $16 → $18 | $11.49 | +56.66% | 9 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $6.07 | +180.07% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $1.61 | +272.67% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $255.46 | +9.61% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.78 | - | 7 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $12.75 | +41.18% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.32 | - | 10 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $2 → $3 | $7.77 | -61.39% | 3 | May 10, 2022 |
Exelixis
Jan 27, 2025
Maintains: Market Outperform
Price Target: $41
Current: $33.15
Upside: +23.68%
Jasper Therapeutics
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $70
Current: $6.06
Upside: +1,055.12%
Context Therapeutics
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $0.91
Upside: +337.97%
enGene Holdings
Dec 23, 2024
Reiterates: Market Outperform
Price Target: $18
Current: $6.70
Upside: +168.66%
CRISPR Therapeutics AG
Dec 20, 2024
Reiterates: Market Outperform
Price Target: $86
Current: $41.59
Upside: +106.78%
Elevation Oncology
Dec 19, 2024
Reiterates: Market Outperform
Price Target: $7
Current: $0.69
Upside: +909.81%
Relay Therapeutics
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $4.47
Upside: +369.80%
Vor Biopharma
Dec 10, 2024
Reiterates: Market Outperform
Price Target: $12
Current: $1.42
Upside: +745.07%
Solid Biosciences
Dec 10, 2024
Initiates: Market Outperform
Price Target: $15
Current: $3.18
Upside: +371.70%
Prime Medicine
Dec 10, 2024
Initiates: Market Outperform
Price Target: $10
Current: $2.80
Upside: +257.14%
Dec 4, 2024
Reiterates: Market Outperform
Price Target: $20
Current: $4.46
Upside: +348.43%
Nov 12, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $1.50
Upside: +233.33%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.00
Upside: -
Oct 14, 2024
Maintains: Market Outperform
Price Target: $16 → $18
Current: $11.49
Upside: +56.66%
Sep 16, 2024
Reiterates: Market Outperform
Price Target: $17
Current: $6.07
Upside: +180.07%
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $1.61
Upside: +272.67%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $255.46
Upside: +9.61%
Oct 23, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.78
Upside: -
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $12.75
Upside: +41.18%
Jan 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $10.32
Upside: -
May 10, 2022
Maintains: Market Outperform
Price Target: $2 → $3
Current: $7.77
Upside: -61.39%